<DOC>
	<DOCNO>NCT03034564</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled trial compare droxidopa placebo fatigue Parkinson 's Disease . The primary outcome measure change Parkinson 's Disease Fatigue Scale , 16-item scale measure physical effect fatigue well impact fatigue daily functioning activity , include socialization . Secondary outcomes PDQ-39 , 39-item self-report questionnaire assess Parkinson 's disease-specific health relate quality last month 8 different dimension function well-being , Epworth Sleepiness Scale , questionnaire query 8 situation subject rate likelihood fall asleep . There screen visit ( SC ) , baseline visit ( BL ) , 2 clinic visit 6 12 week ( V01 , V02 ) , telephone contact 4 week 8 week ( T1 , T2 ) . In-person visit include review informed consent , concomitant medication review , adverse event review , pill count , vital sign ( include supine blood pressure ) , outcome measurement . Telephone visit include review informed consent , concomitant medication review , adverse event review .</brief_summary>
	<brief_title>A Randomized , Double-Blind , Placebo-Controlled Study Droxidopa Fatigue Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Parkinsonian Disorders</mesh_term>
	<mesh_term>Droxidopa</mesh_term>
	<criteria>Diagnosis Parkinson 's Disease Have normal kidney function ( determined screen visit blood sample analysis ) , active medical diagnosis associate fatigue No orthostatic symptom ( i.e . light headedness , blur vision , and/or muscle weakness ) No objective orthostasis ( significant drop blood pressure stand ) No supine hypertension ( high blood pressure lay ) judge clinical significance investigator Wellcontrolled depression Stable dopaminergic medication regimen 6 week prior screen No concurrent use fludrocortisone , midodrine , medication may raise blood pressure PD Fatigue Scale Score 50 Diagnosis Atypical Parkinsonism ( symptoms mimic PD without PD diagnosis ) Prior Intolerance droxidopa SNRI TCA class ( antidepressant ) medication ( irrespective indication ) Use activate agent ( amantadine , modafinil , methylphenidate related stimulant ) Significant cardiac disease history Significant kidney disease history , creatinine ( chemical find blood ) great 1.5 mg/dl baseline Poorly control depression Women pregnant breastfeeding Significant history Gastro Intestinal disease may interfere absorption ( gastric bypass , inflammatory bowel disease )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>